title: Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
abstract: Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that mediates antitumor activities upon activation. A current strategy to harness iNKT cells for cancer treatment is endogenous iNKT cell activation using patient-derived dendritic cells (DCs). However, the limited number and functional defects of patient DCs are still the major challenges for this therapeutic approach. In this study, we investigated whether human embryonic stem cells (hESCs) with an ectopically expressed CD1d gene could be exploited to address this issue. Using a lentivector carrying an optimized expression cassette, we generated stably modified hESC lines that consistently overexpressed CD1d. These modified hESC lines were able to differentiate into DCs as efficiently as the parental line. Most importantly, more than 50% of such derived DCs were CD1d+. These CD1d-overexpressing DCs were more efficient in inducing iNKT cell response than those without modification, and their ability was comparable to that of DCs generated from monocytes of healthy donors. The iNKT cells expanded by the CD1d-overexpressing DCs were functional, as demonstrated by their ability to lyse iNKT cell-sensitive glioma cells. Therefore, hESCs stably modified with the CD1d gene may serve as a convenient, unlimited, and competent DC source for iNKT cell-based cancer immunotherapy.
authors.affiliation: Institute of Bioengineering and Nanotechnology, Singapore; Department of Biological Sciences, National University of Singapore, Singapore.
authors.forename: Jieming
authors.initials: J
authors.lastname: Zeng
authors.forename: Shu
authors.initials: S
authors.lastname: Wang
mesh_terms: D055610:Antigens, CD1d / Q000235:genetics* / Q000378:metabolism; D001932:Brain Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002455:Cell Division / Q000276:immunology; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology; D053595:Embryonic Stem Cells / Q000166:cytology / Q000502:physiology; D005434:Flow Cytometry; D015870:Gene Expression / Q000276:immunology; D005910:Glioma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology; D055611:Natural Killer T-Cells / Q000166:cytology* / Q000276:immunology; D019076:Transgenes / Q000276:immunology
chemical_list: D055610:Antigens, CD1d; C526877:CD1D protein, human
keywords: CD1d; Dendritic cell; Genetic modification; Immunotherapy; Invariant natural killer T cell; Stem cell